Povidone iodine (iodopovidone)
(Synonyms: 聚乙烯吡咯烷酮碘; iodopovidone) 目录号 : GC32325
A microcide
Cas No.:25655-41-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | Each bacterial isolate is washed twice with phosphate-buffered saline (PBS, pH 7.2), centrifuged for 10 min at 1932xg at 20°C, and suspended in 3 mL of nutrient broth, adjusted to a turbidity equivalent of 0.5 McFarland standard. The bacterial suspension is diluted 1:100 with MHB to a final inoculum of 106 colony-forming units (cfu)/mL. For each bacterial strain, two rows of a 96-well microtitre plate are filled with the final bacterial inoculum (50 μL per well) and 50 μL of each serial dilution of ILαD. The procedure is repeated for the Povidone iodine (PVP-I) serial dilutions[1]. |
Animal experiment: | The mice are divided into 6 groups as follows: 1) saline+vehicle (control group), 2) Dp+vehicle, 3) Dp+BZK, 4) Dp+Povidone iodine (PVP-I), 5) Dp+Et-OH, and 6) Dp+CHG. Animals in the experimental groups are exposed to the allergen through the subcutaneous injection of 5 µg of Dp dissolving in 10 µL of saline in the ventral side of the right ear 2 to 3 days a week (a total of 8 times) under anesthesia with 4% halothane. Animals in the control group are not sensitized, receiving a subcutaneous injection of 10 µL of saline in the ventral side of the right ear. Animals receive an application of antiseptic agent are exposed to the allergen and treated with 0.2% (w/v) benzalkonium chloride (Dp+BZK), 10% (w/v) povidone-iodine (Dp+PVP-I), 80% (v/v) ethanol (Dp+Et-OH) or 0.5% (v/v) chlorhexidine gluconate (Dp+CHG). These agents are applied a total of 15 times during the experimental period. The BZK, Povidone iodine (PVP-I), Et-OH, and CHG are dissolved in 25 µL of injection water and applied gently to the dorsal side of the right ear using a micropipette with a fine plastic tip. The animals in the Dp+vehicle and control groups receive 25 µL of injection water. All animals are sacrificed on the last day of the experiment (day 18)[2]. |
References: [1]. Zisi AP, et al. Iodine-lithium-alpha-dextrin (ILαD) against Staphylococcus aureus skin infections: a comparative study of in-vitro bactericidal activity and cytotoxicity between ILαD and povidone-iodine. J Hosp Infect. 2017 Jul 20. pii: S0195-6701(17)30395-X. | |
Povidone-iodine is a microcide with broad-spectrum activity against bacteria, fungi, viruses, and protozoans.1 It reduces total anaerobic and aerobic bacterial counts in vitro in dog feces when applied topically as a 10% solution.2 Povidone-iodine decreases bacterial counts and the occurrence of anastomotic leaks in a dog model of emergent resection and anastomosis of the sigmoid colon when applied in situ at a concentration of 10% v/v. Topical administration of povidone-iodine (10% v/v) also reduces bacterial counts on the skin of cynomolgus monkeys.3 Formulations containing povidone-iodine have been used to disinfect skin before and after surgery.
1.Eggers, M., Eickmann, M., Kowalski, K., et al.Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped virusesBMC Infect. Dis.15:375(2015) 2.Jones, F.E., DeCosse, J.J., and Condon, R.E.Evaluation of "instant" preparation of the colon with povidone-iodineAnn. Surg.184(1)74-79(1976) 3.Nakata, H., Tsubotani, Y., Nii, T., et al.Effects of olanexidine gluconate on preoperative skin preparation: An experimental study in cynomolgus monkeysJ. Med. Microbiol.66(5)678-685(2017)
| Cas No. | 25655-41-8 | SDF | |
| 别名 | 聚乙烯吡咯烷酮碘; iodopovidone | ||
| Canonical SMILES | O=C1N(C(C)CC)CCC1.I[F,Cl,Br,I]I.[n].[n:x].[=].[10:1] | ||
| 分子式 | 分子量 | ||
| 溶解度 | DMSO: soluble,Water: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Povidone iodine in wound healing: A review of current concepts and practices
Int J Surg 2017 Aug;44:260-268.PMID:28648795DOI:10.1016/j.ijsu.2017.06.073.
Background: Of the many antimicrobial agents available, iodophore-based formulations such as Povidone iodine have remained popular after decades of use for antisepsis and wound healing applications due to their favorable efficacy and tolerability. Povidone iodine's broad spectrum of activity, ability to penetrate biofilms, lack of associated resistance, anti-inflammatory properties, low cytotoxicity and good tolerability have been cited as important factors, and no negative effect on wound healing has been observed in clinical practice. Over the past few decades, numerous reports on the use of Povidone iodine have been published, however, many of these studies are of differing design, endpoints, and quality. More recent data clearly supports its use in wound healing. Methods: Based on data collected through PubMed using specified search criteria based on above topics and clinical experience of the authors, this article will review preclinical and clinical safety and efficacy data on the use of Povidone iodine in wound healing and its implications for the control of infection and inflammation, together with the authors' advice for the successful treatment of acute and chronic wounds. Results and conclusion: Povidone iodine has many characteristics that position it extraordinarily well for wound healing, including its broad antimicrobial spectrum, lack of resistance, efficacy against biofilms, good tolerability and its effect on excessive inflammation. Due to its rapid, potent, broad-spectrum antimicrobial properties, and favorable risk/benefit profile, Povidone iodine is expected to remain a highly effective treatment for acute and chronic wounds in the foreseeable future.
Povidone-iodine enhanced underwater tape
J Mater Chem B 2022 Dec 7;10(47):9906-9913.PMID:36448473DOI:10.1039/d2tb02115c.
Realizing rapid and stable bonding under humid conditions has remained a challenge in adhesion science and wound dressing. In this study, polyacrylate-based underwater tape with water-enhanced adhesion and antimicrobial performance was designed and synthesized. Good underwater adhesion performance is achieved through the reasonable selection of comonomers, among which 4-hydroxybutyl acrylate (4-HBA) and isobornyl acrylate (IBOA) provide rich hydrogen bond interactions and a rigid side chain stable structure, respectively. The former effectively increases the interface strength between the tape and the substrate, while the latter ensures that the tape can maintain a good cohesion strength under water. Besides, Povidone iodine (PVP-I2) as a reinforcing filler and germicidal factor endows the tape with tunable mechanical properties and impressive antimicrobial abilities. This work provides a facile approach to prepare a wet adhesive for medical and industrial fields which can be used as wound dressing and underwater adhesive materials.
Comparison of topical honey and povidone iodine-based dressings for wound healing: a systematic review and meta-analysis
J Wound Care 2021 Apr 1;30(Sup4):S28-S36.PMID:33856925DOI:10.12968/jowc.2021.30.Sup4.S28.
Objectives: In this review and meta-analysis, we analyse the evidence to compare the efficacy of honey and povidone iodine-based dressings on the outcome of wound healing. Method: A systematic literature search was performed using PRISMA guidelines in academic databases including MEDLINE, Scopus, Embase and CENTRAL. A meta-analysis was carried out to assess the effect of honey and povidone iodine-based dressings on mean healing duration, mean hospital stay duration and visual analogue scale (VAS) score of pain. Results: From the search, 12 manuscripts with a total of 1236 participants (mean age: 40.7卤11.7 years) were included. The honey-based dressings demonstrated a medium-to-large effect in reduction of mean healing duration (Hedge's g: -0.81), length of hospital stay (-3.1) and VAS score (-1.2) as compared with the povidone iodine-based dressings. We present evidence (level 1b) in favour of using honey for improvement of wound recovery as compared with Povidone iodine. Conclusion: This review and meta-analysis demonstrate beneficial effects of honey-based dressings over povidone iodine-based dressings for wound recovery.
Povidone iodine for the treatment of adenoviral conjunctivitis
Clin Exp Optom 2021 Apr;104(3):308-314.PMID:33689609DOI:10.1080/08164622.2021.1877532.
Adenoviral conjunctivitis is the most common cause of ocular viral infection in the world, but currently has no approved therapeutic treatments. The antiseptic povidone-iodine (PVP-I) has been used as an off-label treatment for the condition, but high-quality evidence for its use is limited. This paper aims to review the literature surrounding the use of PVP-I in the management of adenoviral conjunctivitis. Unfortunately, treatment regimens, inclusion criteria, outcome measures, and review periods vary widely between studies, making direct comparisons between outcomes difficult. The majority of studies investigate daily instillation of 0.4 to 2.0% PVP-I rather than one-time instillation of PVP-I as has been used anecdotally in practice. In addition, only one treatment arm investigates daily PVP-I alone, with no significant difference in the duration of disease or clinical outcome compared to placebo. All other treatment arms investigate PVP-I in combination with dexamethasone which generally improve outcomes. Tolerability of PVP-I is generally good for low concentrations <1.0%, but efficacy of treatment is generally reported to be concentration dependent. Future research should investigate the optimal concentration, dosing regimen and role of each agent in combination treatment and aim to use laboratory techniques to improve diagnosis and provide quantifiable outcomes.
High Ingestion Rate of Iodine from Povidone-Iodine Mouthwash
Biol Trace Elem Res 2022 Aug;200(8):3902-3909.PMID:34674109DOI:10.1007/s12011-021-02978-7.
Iodine-based mouthwash and throat sprays contain Povidone iodine (PVP-I) for disinfection. PVP-I mouthwash has been commonly used for decades in Japan and other countries and frequent and/or prolonged use of PVP-I mouthwash can induce transient hypothyroidism. To assess the amount of iodine ingested from an oral rinse, 22 healthy adult volunteers (mean age: 48.1, 29-70 years) were recruited for the study. The subjects were instructed to rinse for 15 s three times with 20 mL of commercially available PVP-I mouthwash diluted into 0.23% or pure water. This method is a standardized method of gargling recommended by the manufacturers. The total iodine in the PVP-I mouthwash was measured with inductively coupled plasma-mass spectrometry. Although the 7% PVP-I mouthwash contains 7 mg of effective iodine/mL, 24.3 mg/mL of iodine was detected in the solution. The median value and ratio of the total iodine ingested were 5.0 mg (range: 2.6-10.8 mg) and 20.5% (range: 10.6-44.5%), respectively. The iodine species released from the PVP-I mouthwash are effective iodine (PVP銉籲HI3, I3-, and I2) and I-; however, the amount and types of iodine actually absorbed into the bloodstream are unknown. PVP-I mouthwash should be used carefully since around 5 mg of iodine could theoretically enter the body with one gargle which exceeds the tolerable upper intake level of iodine for adults. This study was prospectively registered to University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) on March 29, 2021, with the study ID of UMIN000043770.